[PDF] Top 20 The clinical development of rectal microbicides for HIV prevention

... candidate microbicides being evaluated by the MTN, in response to needs within the broader microbicide/PrEP field, or in response to specific requests by other product ...Protocol development is coordinated ... See full document

... Microbicide Development Program (MDP), ...for HIV Prevention Research, for his participation in project design and technical expertise, and Timothy ... See full document

... funding HIV prevention to economic and scien- tific interests of the donors ...and microbicides, are primarily privately owned medical pharmaceutical com- panies or scientific research institutes ... See full document

... successful development of long-acting steroid-releasing vaginal ring devices for the treatment of menopausal symptoms and contraception, there is now consider- able interest in applying similar devices to the ... See full document

... fied themselves at high risk may have been the first to come forward to participate in the Feasibility Studies, and that the introduction of gel in the trial may further facili- tate condom use in all participants as ... See full document

... of microbicides under development is vaginal milieu protectors that work to maintain, restore, or enhance the natural protective mechanisms within the ... See full document

... the development of microbicides, their accept- ability and perceived acceptability of their ...explain microbicides in the context of heterosexual contact, how it will be ap- plied and the ... See full document

... The most disadvantaged women in society are also at high- est risk for HIV. These women include commercial sex workers, women who cannot negotiate safer sex, women who cannot ensure their partners’ faithfulness, ... See full document

... the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV), many children, and particularly those in resource-limited settings, continue to acquire HIV infection ... See full document

... Eleven clinical microbicide studies, representing six candidate products, have failed over the last 20 years and not a single microbicide is currently publicly ...generation microbicides acted as ... See full document

... limiting HIV dis- ease ...cross-reactive HIV-1 specific neutralising activity in serum and the clinical course of HIV-1 infection ...of HIV- infected patients established before the ... See full document

... of microbicides associated with higher rates of HIV transmission can affect the composition of the vaginal microbiota, although it is impossible to say whether these changes are specific to the active agent ... See full document

... available prevention methods are outside the control of ...vaginal microbicides to prevent sexual transmission of HIV from men to women in recent ...first microbicides evaluated were ... See full document

... PJ, MF, EE, and DMC were involved in the design, data analy- sis, and interpretation of the human Proof of Mechanism study and the Proof of Principle trial. KP and NK were involved in the design, data generation, and ... See full document

... with HIV infection and are well equipped to prescribe PrEP; however, their practice is lim- ited to patients with established HIV ...without HIV infection but may lack the training necessary to ... See full document

... Among all subjects, six patients had some levels of resis- tance to RPV at baseline, but this did not result in treatment failure (defined as > 50 HIV-1 RNA copies/mL). No INSTI mutations were detected at ... See full document

... Results: Progressive motility was completely abolished in all cell types between pH 5.5 and 6.0. Concomitantly, at and below pH 5.5, the intracellular pH of PBMCs dropped precipitously to match the extracellular medium ... See full document

... of HIV infection compared to the general popula- tion [14–18], defined as either men who have sex with men (MSM) or transgender (TG) persons or female sex workers (FSWs) or injecting drug users ...on ... See full document

... I clinical trial RisVac02 ...Thirty HIV-1 negative volunteers were given three intramuscular injec- tions of MVA-B or placebo at weeks 0, 4 and 16 and fol- lowed for one ...and HIV neutral- izing ... See full document

... In THRIVE and ECHO, rilpivirine was non-inferior to efavirenz in treatment-naïve patients. However, the primary composite endpoint, combining either virologic failure or treatment discontinuation mandates that results ... See full document